BRISBANE, Calif., October 11, 2024–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company’s newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares of CareDx common stock (“Option”), as an inducement material to entering into employment with CareDx, pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Board of Directors in August 2019 in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years in four equal annual installments beginning on October 8, 2025, the first…
